BDD With UDCA Therapy After Laparoscopic Cholecystectomy (BULQ-LC)
Prospective Study for the Effects of Biphenyl Dimethyl Dicarboxylate and Ursodeoxycolic Acid Therapy on Liver Function and Quality of Life After Laparoscopic Cholecystectomy
Prospective Study for the Effects of Biphenyl Dimethyl Dicarboxylate and Ursodeoxycolic Acid Therapy on Liver Function and Quality of Life After Laparoscopic Cholecystectomy
Primary endpoint: peak level of postoperative AST (aspartate transaminase) and postoperative ALT (alanine tansaminase)
Secondary endpoint: postoperative GIQLI (Gastrointestinal Quality of Life index) score
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Contact
Study Contact
- Name: Huisong Lee, M.D., Ph.D.
- Phone Number: +82-2-2650-5694
- Email: huisong.lee@ewha.ac.kr
Study Locations
-
-
-
Seoul, Korea, Republic of, 07985
- Recruiting
- Ewha Womans University Mokdong Hospital
-
Contact:
- Huisong Lee, M.D., Ph.D.
- Phone Number: +82-2-2650-5694
- Email: huisong.lee@ewha.ac.kr
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients scheduled for surgery due to chronic cholecystitis and acute cholecystitis
Exclusion Criteria:
- Failure to obtain consent
- Under 19 years
- If you have intellectual ability to understand this study
- When performing cholecystectomy with other operations
- Total bilirubin levels> 2 mg / dl
- If you are enrolled in another clinical trial
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
|
Dosage: 1 capsule of placebo, 3 times daily Time of administration: 30 minutes after meal Duration of administration: From the day before surgery to 4 weeks after surgery
Other Names:
|
|
Active Comparator: BDD with UDCA
Postoperative BDD with UDCA treatment
|
Dosage: Udex 1 capsule, 3 times daily Time of administration: 30 minutes after meal Duration of administration: From the day before surgery to 4 weeks after surgery
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Serum Aspartate Aminotransferase
Time Frame: Postoperative 30 days
|
Serum aspartate aminotransferase level (U/ml) (continuous variable)
|
Postoperative 30 days
|
|
Serum Alanine Aminotransferase
Time Frame: Postoperative 30 days
|
Serum Alanine Aminotransferase level (U/ml) (continuous variable)
|
Postoperative 30 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
GIQLI (Gastrointestinal Quality of Life Index)
Time Frame: Postoperative 30 days
|
Score of Quastionare for postoperative quality of life by GIQLI (Range, 0 - 180)
|
Postoperative 30 days
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Huisong Lee, M.D., Ph.D., Ewha Womans University Mokdong Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- BULQ-LC trial
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.